Transglutaminase 2 regulates ovarian cancer metastasis by modulating the immune microenvironment

Ovarian cancer is the most lethal gynecological malignancy. Deepening our knowledge of the interactions within the tumor microenvironment (TME) is important for discovering new targeted treatment strategies. Transglutaminase 2 (TG2) is a protein implicated in many biological and pathophysiological p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Frontiers in immunology Jg. 16; S. 1639853
Hauptverfasser: Ibrahim, Dalia, Grondin, Melanie, Galpin, Kristianne, Asif, Sara, Thompson, Emily, Nersesian, Sarah, Abou-Hamad, John, Echaibi, Maryam, Rodriguez, Galaxia M., Navals, Pauline, Macdonald, Elizabeth, Ryan, Brianna, Cook, David P., Keillor, Jeffrey W., Vanderhyden, Barbara C.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Switzerland Frontiers Media S.A 24.07.2025
Schlagworte:
Animals
Cell Line, Tumor
Disease Models, Animal
Female
GTP-Binding Proteins
Humans
immune modulation
Immunology
metastasis
Mice
Neoplasm Metastasis
ovarian cancer
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - immunology
Ovarian Neoplasms - pathology
Protein Glutamine gamma Glutamyltransferase 2 - antagonists & inhibitors
Protein Glutamine gamma Glutamyltransferase 2 - metabolism
targeted therapy
transglutaminase 2
Transglutaminases - antagonists & inhibitors
Transglutaminases - genetics
Transglutaminases - metabolism
Tumor Microenvironment - immunology
Xenograft Model Antitumor Assays
targeted therapy
transglutaminase 2
immune modulation
metastasis
ovarian cancer
ISSN:1664-3224, 1664-3224
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Ovarian cancer is the most lethal gynecological malignancy. Deepening our knowledge of the interactions within the tumor microenvironment (TME) is important for discovering new targeted treatment strategies. Transglutaminase 2 (TG2) is a protein implicated in many biological and pathophysiological processes, including promoting tumor progression in ovarian cancer. Its role in disease progression has been studied in ovarian cancer cells; however, its role in the ovarian TME is less understood. In this study, for the first time, we assessed the therapeutic potential of novel covalent irreversible small molecule TG2 inhibitors in xenograft models of ovarian cancer. We further elucidated the role of TG2 in ovarian cancer cells and syngeneic tumors by immune phenotyping using flow cytometry, RNA sequencing, and immunohistochemistry to characterize the contribution of TG2 in the TME to the metastatic process of ovarian cancer. To investigate the transamidation catalytic and GTP binding activities of TG2 in cancer cells, we used several TG2 inhibitors, some of which decreased invasiveness of human ovarian cancer cell lines in vitro and lengthened survival of the SKOV3 xenograft model. Using the ID8 and KPCA.B syngeneic mouse models of ovarian cancer, we defined the contribution of TG2 in the TME to the metastatic process. Lack of TG2 in the TME prolonged survival in the ID8 metastatic model, but it did not affect survival in the non-metastatic KPCA.B model. Through extensive analysis of the immune composition in both the primary tumor and metastatic ascites in the ID8 model, we discovered that the lack of host TG2 resulted in decreased frequency of immunosuppressive tumor-associated macrophages, and increased frequency of T cells, NK cells, and B cells. RNA sequencing of the primary tumors with or without TG2 present in the TME, revealed an enrichment of pathways related to B cell activation and regulation. These findings highlight the importance of TG2 in the TME for ovarian cancer metastasis, potentially by activation of humoral immunity and specifically highlight a crucial role for TG2 in modulating B cells to prolong survival in mouse models of ovarian cancer.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Ying Zhang, Shimane University, Japan
Edited by: Noha Mousaad Elemam, University of Sharjah, United Arab Emirates
Reviewed by: Tomasz Trombik, Medical University of Lublin, Poland
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2025.1639853